AUTHORS
Yucai Wang, MD, PhD, Paul J. Hampel, MD2, Betsy R. Knopf, MS3, Lindsey Elizabeth Roeker, MD4, Eli Muchtar, MD5, Wei Ding6, Peyton Schumacher7, Jithma Abeykoon, MD8, Thomas Witzig, MD9, Grzegorz Nowakowski, MD10, Stephen Maxted Ansell, MD, PhD11, Amy L. Behnken12, Catherine C. Wagner, CNP13, Emily G. Brigham14, Amber B Koehler, P.A.-C., M.S.15, Robin R. Klebig, CNP, MSN16, Patricia A. Gerber17, Cecilia A. Merrigan18, Rachel J. Bailen, PharmD19, Casey N. Aitken20, Cheryl A. Melton21, Min Shi, M.D.22, Saad Kenderian, M.B., Ch.B.23, Neil E Kay, M.D.24, Sameer A. Parikh, MBBS25
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction: Fixed-duration frontline treatment options for CLL/SLL include venetoclax plus obinutuzumab or a covalent BTK inhibitor (BTKi; such as acalabrutinib) plus venetoclax. Pirtobrutinib is a highly selective, non-covalent BTKi approved by FDA for CLL/SLL after prior BTKi exposure, and it has also demonstrated excellent efficacy in the frontline. In this phase 2 study, we evaluated MRD-guided time-limited frontline therapy with pirtobrutinib plus venetoclax in patients with CLL/SLL.
Methods: Key inclusion criteria included treatment-naïve CLL/SLL, an indication for treatment per iwCLL 2018 guidelines, ECOG PS 0-2, and adequate hematologic and hepatorenal function. Key exclusion criteria included Richter transformation and CNS involvement. Treatment consisted of a 3-cycle pirtobrutinib lead-in, followed by 12-24 cycles of pirtobrutinib plus venetoclax. Treatment duration was guided by MRD status assessed using clonoSEQ. Patients who achieved undetectable MRD at 10-4 (uMRD4) in both peripheral blood (PB) and bone marrow (BM) after Cycle 15 discontinued therapy. Those with detectable MRD4 continued for 6 additional cycles and discontinued after Cycle 21 if uMRD4 was achieved in both PB and BM; otherwise, they continued for 6 more cycles and discontinued after Cycle 27 regardless of MRD status. The primary endpoint is the rate of uMRD4 in both PB and BM after Cycle 15. Using a one-stage binomial design, 65 evaluable patients were required to test an alternative rate of 60% versus a null rate of 40%. The study would be considered successful if at least 33 of the 65 evaluable patients achieved uMRD4 in both PB and BM.
Results: From Feb 2023 to Sept 2025, 71 patients were enrolled and treated. The median age was 62 years (range, 34-84), and 28 patients (39%) were >65 years; 27 (38%) were female. IGHV was unmutated in 41 (58%) patients; 7 (10%) had del17p and/or TP53 mutation, 8 (11%) had del11q, and 38 (54%) had high or very high risk CLL-IPI.
At data cutoff (July 27, 2026), 8 patients received <15 cycles (5 still on treatment, 3 discontinued due to cytopenias, lung cancer, and insurance denial, respectively) and 63 patients received ≥15 cycles. Among the first 65 evaluable patients by intention-to-treat (including 3 who discontinued treatment <15 cycles and the first 62 patients who received ≥15 cycles), 36 (55%; 95% CI 43%-68%) achieved uMRD4 in PB and BM after Cycle 15 and discontinued treatment. Thus, this trial met its primary endpoint.
Among the 63 patients who received ≥15 cycles, 41 (65%) achieved uMRD4 in PB after Cycle 15, 36 (57%) in BM, with 36 (57%; 95% CI 44%-70%) achieving uMRD4 in both. Among the 27 patients with detectable MRD4 after Cycle 15, 18 had completed Cycle 21 with 7 achieving uMRD4 in both PB and BM, and 8 had completed Cycle 27 with 2 achieving uMRD4 in both PB and BM.
For the 63 patients who received ≥15 cycles of treatment, the objective response rate after Cycle 15 was 98%, including 73% complete response and 25% partial response.
The median follow-up was 22 months (range 6-40) at the data cutoff for the entire cohort. No disease progression or death had occurred. The 18-month PFS and OS rates were both 100%.
Most common treatment-related adverse events (TRAEs; ≥15%) included neutrophil count decreased (87%), lymphocyte count decreased (69%), diarrhea (48%), bruising (46%), platelet count decreased (46%), nausea (41%), anemia (32%), hypertension (27%), fatigue (25%), arthralgia (21%), rash maculo-papular (20%), hematuria (18%), and myalgia (15%). The most common grade ≥3 TRAEs (≥3%) included neutrophil count decreased (46%), lymphocyte count decreased (23%), and platelet count decreased (11%). There was no treatment-related atrial fibrillation, febrile neutropenia, or tumor lysis syndrome. Ten patients required dose reduction (pirtobrutinib n=2 and venetoclax n=8) and another 3 patients discontinued all study treatment due to AEs (cytopenias n=2, GI intolerance n=1).
Conclusions: Time-limited frontline pirtobrutinib and venetoclax combination therapy is highly efficacious and overall tolerable in CLL/SLL, with 55% of patients achieving uMRD4 in both PB and BM after approximately 1 year of treatment. MRD-guided time-limited treatment is promising, allowing early treatment discontinuation in patients achieving uMRD4 while providing additional treatment for others to potentially deepen the response. Longer follow-up is needed to assess the durability of responses and long-term safety.
DISCLOSURES
Yucai Wang, MD, PhD: LOXO Oncology - Research Funding; Incyte - Research Funding; AbbVie - Research Funding; AstraZeneca - Research Funding; Genentech - Research Funding; Innocare - Research Funding; Bristol Myers Squibb - Research Funding; Genmab - Research Funding; BeiGene - Research Funding; BeOne Medicines, Ltd - Research Funding; Merck - Research Funding; Eli Lilly and Company - Research Funding; Kite - Research Funding; AbbVie - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Innocare - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); BeOne Medicines, Ltd - Consultancy (Includes expert testimony)